Plasma levels of CRP, CRP-complement complexes, and complement activation products in patients with RA treated with infliximab, classified according to their clinical response (good, moderate, or no response) at 14 weeks after the start of treatment
| Good (n = 9) | Moderate (n = 17) | No response (n = 9) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Plasma levels | Before treatment | After treatment | p Value | Before treatment | After ?treatment | p Value | Before treatment | After treatment | p Value |
| Data are shown as mean (SD) before and after 14 weeks after treatment. p Values show the differences between baseline and the follow up in every group (Wilcoxon matched pairs test). | |||||||||
| CRP | 33 (24.8) | 2.2 (1.8) | <0.01 | 31.6 (25.7) | 15.2 (26.2) | <0.001 | 57.2 (48.6) | 45.6 (44.4) | 0.160 |
| C3b/c | 33.3 (11.8) | 22.8 (6.9) | 0.054 | 24.6 (10.9) | 17.5 (6.4) | <0.01 | 27.4 (9.1) | 34.1 (25.2) | 0.547 |
| C4b/c | 60.1 (49.8) | 58 (45.6) | 0.91 | 37.4 (31.8) | 22.9 (13.4) | 0.120 | 39 (25.5) | 23.4 (6.6) | 0.431 |
| CRP-C3d | 406 (417.5) | 62 (65.2) | <0.05 | 434 (502.4) | 145 (276.6) | <0.001 | 1043 (1249) | 535 (507) | 0.250 |
| CRP-C4d | 632 (686.6) | 83 (142.6) | <0.05 | 370 (379.7) | 148 (334) | <0.01 | 1071 (1403) | 598 (806) | 0.312 |